Todd Applebaum

Vice President of strategy and operations at Maxiom Group

Despite the current regulatory uncertainty, pharmaceutical companies should move forward with planning for serialization and pedigree.

Companies need to avoid operating in a manner that is inconsistent with the priorities established in the strategic sourcing decision.

The supply chain can be used as a tool for managing not only product supply risks, but overall business risks as well.

Many CMO relationships are established while a product is early in clinical or preclinical development.